Dr Sin Chi CHEW
Dr Lingyan WU
Dr Yong Jae SHIN
Dr Ah Jung JEON
Fiona Ni Ni MOE
Ai Leng LIANG
Si Ying CHOO
Primary liver cancer or hepatocellular carcinoma (HCC) imposes significant challenges to healthcare with huge unmet clinical needs. HCC is the second leading cause of cancer-related mortality worldwide in males and 80% of HCC are found in the Asia-Pacific. While early-stage HCC is potentially curable by surgical resection, liver transplantation or radiofrequency ablation, recurrences remain common and limits overall survival. Survival in intermediate stage HCC may be prolonged by loco-regional therapy in in advanced HCC by systemic therapies. Overall, clinical outcomes in HCC remain poorer than that of other common cancers due to the lack of efficacious systemic therapies. The biology of HCC is intrinsically challenging as HCC is the common end-point of a number of etiologies with different molecular pathways. In addition, significant heterogeneity also exists within the same tumor.
Concerted research through an inter-disciplinary approach is thus required to address these challenges. The Program in Translational and Clinical Liver Cancer Research in NCCS initiates and coordinates a multi-national and multi-institutional enterprise with NCCS leading translational research platforms and prospective clinical studies in HCC. Nested within the program is the Secretariat of the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group (17 countries, > 50 sites) which has just completed enrolment of a 2500-patient, 33-site real world data Asia-Pacific HCC Registry (AHCC 08). The AHCC trials group is also currently conducting a 5-country prospective multi-omics study in surgically resected HCC cohort (AHCC 07). In our translational research platforms, we collaborate closely with leading research institutes including the Genome Institute of Singapore (GIS), the Institute of Molecular and Cell Biology (IMCB), Singapore Phenome Centre (SPC), the Translational Immunology Institute (TII), Duke-NUS, Cancer Science Institute (CSI) NUS, Singapore Bioimaging Consortium (SBIC), the Institute for Infocomm Research (I2R) and Samsung Medical Center, South Korea. This multi-institutional collaboration brings together different world-class scientific expertise to bear on the challenges of HCC.
Our current portfolio of clinical studies and translational research platforms include:
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000